Author: Kevin Grogan

Bayer has signed a major deal with Genzyme Corp, including the transfer of its haematological oncology portfolio, and certain rights to Campath, which could net the German group up to $2.8 billion.

The likelihood of GlaxoSmithKline’s Cervarix reaching the US market has been given a boost after the company said it has submitted final data from a key study of the cervical cancer vaccine to the Food and Drug Administration.

Eli Lilly has signed up another drug development partner in India, having inked a cardiovascular research pact with Zydus Cadila.

Novartis is celebrating the news that regulators in the USA have given the thumbs-up to Afinitor for advanced kidney cancer.

AstraZeneca has unveiled new data from the landmark JUPITER study which shows that its cholesterol-lowering blockbuster Crestor significantly reduced the risk of blood clots in the veins.